Regenerative Medicine Solutions published a study by Freedland et al (2026) in the journal Cancer indicating that reaching a prostate-specific antigen level below 0.2 ng/mL is an indicator of improved patient survival in metastatic castration-sensitive prostate cancer patients.
Public source
Publisher name
Public post
What (if any) is the Optimal PSA to Determine Prostate Cancer Treatment Efficacy ? The mathematical modeling of Prostate-Specific Antigen (PSA) decline following surgica…
Company
Regenerative Medicine Solutions
- Industry
- Hospitals
- Location
- Barcelona, ES
- Company size
- 2–10 employees
Latest activity
Latest activity from Regenerative Medicine Solutions
4 signals
Research & Knowledge
Regenerative Medicine Solutions published a study in Science by A. J. Wesolowski et al. (2026) showing that mouse tumors release the enzyme peroxiredoxin 1 (PRDX1) into the interstitial fluid to remove H2O2 near T cells, which weakens T cell receptor signaling.
Research & Knowledge
Regenerative Medicine Solutions published a study of more than 72,000 people showing that those who received the latest shingles vaccine have a lower risk of stroke or heart failure compared to older versions.
Research & Knowledge
Regenerative Medicine Solutions did not claim any business signals about the author's company, but the post discusses a longitudinal single-cell RNA sequencing atlas assembled by Israeli and German researchers for Translational Skin Cancer Research and the German Cancer Consortium.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
CDL Nuclear Technologies
CDL Nuclear Technologies published a recent longitudinal study using F18 FDG-PET/MRI findings that androgen deprivation therapy (ADT) was associated with progressive arterial inflammation in men with prostate cancer.
Research & Knowledge
SunState Medical Specialists
SunState Medical Specialists published a clinical overview of how prostate cancer care has evolved, written for patients, families, and anyone supporting someone through a diagnosis.
Research & Knowledge
SOGUG - Spanish Oncology Genitourinary Group
SOGUG - Spanish Oncology Genitourinary Group published the report Las cifras del cáncer en España 2026 by the Society of Oncology of Medicine (SEOM)–REDECAN, indicating that prostate cancer will be the most common tumor in men in Spain with 34.833 new cases estimated for 2026
Research & Knowledge
Urology Alliance
Urology Alliance published a new article in Urology Times by Justin Cohen, MD, President of UroPartners LLC., part of Urology Alliance, discussing the proactive role of urologists in reaching men who may be least likely to enter the healthcare system early.
Research & Knowledge
Fred Hutch